Akebia Ther Stock Performance
| AKBA Stock | USD 2.26 0.57 33.73% |
On a scale of 0 to 100, Akebia Ther holds a performance score of 5. The firm shows a Beta (market volatility) of 0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Akebia Ther's returns are expected to increase less than the market. However, during the bear market, the loss of holding Akebia Ther is expected to be smaller as well. Please check Akebia Ther's semi deviation, jensen alpha, maximum drawdown, as well as the relationship between the coefficient of variation and sortino ratio , to make a quick decision on whether Akebia Ther's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Akebia Ther are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental drivers, Akebia Ther sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 44.6 M |
Akebia |
Akebia Ther Relative Risk vs. Return Landscape
If you would invest 187.00 in Akebia Ther on December 17, 2024 and sell it today you would earn a total of 34.00 from holding Akebia Ther or generate 18.18% return on investment over 90 days. Akebia Ther is currently generating 0.415% in daily expected returns and assumes 5.6565% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Akebia, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Akebia Ther Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akebia Ther's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akebia Ther, and traders can use it to determine the average amount a Akebia Ther's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0734
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AKBA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.66 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.42 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Akebia Ther is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akebia Ther by adding it to a well-diversified portfolio.
Akebia Ther Fundamentals Growth
Akebia Stock prices reflect investors' perceptions of the future prospects and financial health of Akebia Ther, and Akebia Ther fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akebia Stock performance.
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 488.86 M | ||||
| Shares Outstanding | 218.18 M | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 3.08 X | ||||
| Revenue | 160.18 M | ||||
| EBITDA | (50.47 M) | ||||
| Cash And Equivalents | 143.89 M | ||||
| Cash Per Share | 0.78 X | ||||
| Total Debt | 3.55 M | ||||
| Debt To Equity | 2.15 % | ||||
| Book Value Per Share | (0.22) X | ||||
| Cash Flow From Operations | (40.66 M) | ||||
| Earnings Per Share | (0.33) X | ||||
| Total Asset | 220.67 M | ||||
| Retained Earnings | (1.68 B) | ||||
| Current Asset | 141.02 M | ||||
| Current Liabilities | 11.87 M | ||||
About Akebia Ther Performance
By analyzing Akebia Ther's fundamental ratios, stakeholders can gain valuable insights into Akebia Ther's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Akebia Ther has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Akebia Ther has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 426 people.Things to note about Akebia Ther performance evaluation
Checking the ongoing alerts about Akebia Ther for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akebia Ther help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akebia Ther had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 160.18 M. Net Loss for the year was (69.41 M) with profit before overhead, payroll, taxes, and interest of 134.03 M. | |
| Akebia Ther currently holds about 143.89 M in cash with (40.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78. |
- Analyzing Akebia Ther's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akebia Ther's stock is overvalued or undervalued compared to its peers.
- Examining Akebia Ther's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akebia Ther's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akebia Ther's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akebia Ther's stock. These opinions can provide insight into Akebia Ther's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |